5 th <strong>European</strong> <strong>Congress</strong> <strong>of</strong> <strong>Virology</strong>28. GASTROINTESTINAL VIRALINFECTIONSPosters: REF 578 to REF 589REF 578Human Enteric Adenoviruses 40 and 41 in 293 and Caco 2 cellsCasandra MANGROO 1 , Dr. Martha BROWN 1,21 Department <strong>of</strong> Laboratory Medicine & Pathobiology, University <strong>of</strong>Toronto, Toronto, CANADA; 2 Department <strong>of</strong> Molecular Genetics, University<strong>of</strong> Toronto, Toronto, CANADAFastidious human enteric adenoviruses, serotypes 40 and 41 (HAdV 40/41;species F), are important agents <strong>of</strong> paediatric enteritis. Unlike other adenoviruses,they grow to high titre in the small intestine but typically donot cause disease elsewhere in the body. In cell culture, infectivity is poor,even in 293 cells, whose endogenous HAdV 5 E1 sequences complementthe low level E1 expression <strong>of</strong> HAdV 40/41. Recent work in this laboratoryidentified a major, though incomplete, block in virion uptake in 293and A549 (lung epithelial) cells. A comparable block in intestinal epithelial(Caco 2) cells, grown under conditions optimized for susceptibility toHAdV 40/41, was unexpected. Caco 2 cells are less susceptible to infectionas cells become differentiated with time, and are most susceptible insub confluent undifferentiated cultures, in particular, when the edges areexposed. Recent experiments using HAdV 41 EGFP and 293 cells haveaddressed the hypothesis that virions are stable during passage through thestomach, but require modification by intestinal conditions for successfulentry/genome delivery. Consistent with the hypothesis, virion infectivitywas increased by exposure to synthetic gastric fluid followed by syntheticintestinal fluid, as determined by flow cytometric analysis <strong>of</strong> infectedcultures. The unexpected finding was that exposure to gastric fluid alonewas sufficient for the increased infectivity. Subsequent experiments willaddress structural modifications induced by gastric conditions and stepsin the entry pathway facilitated by these modifications.REF 579Validation and performance <strong>of</strong> an internally controlled multiplexedreal time PCR run on the BDMAX for the detection <strong>of</strong> Norovirus(NoV) in 7 day working systemKate TEMPLETON, Juliet KENICER, Julie WHITE, PeterMCCULLOCHNHS Lothian, Edinburgh, UNITED KINGDOMThe study aim was to assess performance <strong>of</strong> a multiplexed NoV GI/GIIPCR with EAV internal control on the BDMAX. A secondary objectivewas to assess BDMAX as a suitable platform for routine testing by nonpr<strong>of</strong>essionally registered staff.The initial validation phase collected 337 samples in January and February2012. 312 samples were faecal specimens and 25 were vomit; all patientshad diarrhoea or vomiting or both. 1 ml suspensions were made by adding25 mg <strong>of</strong> solid sample or two drops <strong>of</strong> liquid sample to H2O containingEAV, spun down and extracted both on the easyMAG (Biomerieux) andthe BDMAX (Becton Dickinson). PCR multiplex was performed and analysedon the ABi 7500 or the BDMAX. Following the validation phase theassay was run on the BDMAX for routine diagnosis and then switched backto the easyMAG and ABi to compare performance. The BDMAX NoVmultiplex was 94% sensitive (96/102) and 99% specific (233/235.) 8.6%<strong>of</strong> positives were GI and the rest were GII. The assay on the BDMAX had2% inhibition and 10.6% inhibition on the EasyMAG/ABi. 1414 sampleswere tested routinely: 361 on the EasyMAG/ABi 7500 and 1053 on theBDMAX. Mean turnaround time was 3 Hrs 47mins on EasyMAG/ABiand 3 Hrs 55mins on BDMAX. During 2011/12, only 29% <strong>of</strong> NoV testsamples were achieving 15:15 cut <strong>of</strong>f time for resulting. Over the sameperiod during 2012/13 this improved to 75%. The BDMAX could be runmore frequently with minimal hands on time and uncomplicated ease <strong>of</strong>use. The validated NoV Multiplex PCR performed well on the BDMAXand brought significant practical advantages including walk away functionality,minimal hands on time and low level <strong>of</strong> technical ability requiredto operate the machine. This allowed routine NoV diagnosis to be carriedout 7 days by non pr<strong>of</strong>essionally registered staff and helped minimise theimpact <strong>of</strong> NoV sample numbers on other molecular tests.REF 580New Sydney 2012 strain <strong>of</strong> norovirus detected in patients with acutegastroenteritis in PortugalInês COSTA 1 , João MESQUITA 3 , Elisabete VEIGA 1 , MónicaOLEASTRO 1 , Maria SÃO JOSÉ NASCIMENTO 21 Laboratório Nacional de Referência das Infeções Gastrintestinais,Departamento de Doenças Infeciosas, do Instituto Nacional de S, Lisboa,PORTUGAL; 2 Laboratório de Microbiologia, Departamento de CiênciasBiológicas, Faculdade de Farmácia da Universidade do Porto, Porto,PORTUGAL; 3 Escola Superior Agrária, Instituto Politécnico de Viseu,Viseu, PORTUGALNorovirus (NoV) is the leading cause <strong>of</strong> diarrheal disease across all agegroups as well as half <strong>of</strong> all gastroenteritis outbreaks worldwide. Surveillancesystems showed an increase in NoV activity in late 2012 relatedto the emergence <strong>of</strong> a new NoV genotype II.4 variant, termed Sydney 2012,with the first report coming from Australia in March 2012. Until date, Sydneyvariant circulation in Portugal has not been reported. Aim: To studythe genetic variation <strong>of</strong> NoVs strains circulating in Portugal in patientswith acute gastroenteritis from May 2011 to December 2012. Methods:A total <strong>of</strong> 36 NoVs positive samples were studied. Viral RNA was extractedusing NucliSens ® easyMAG TM (bioMérieux) and tested with primerstargeting the POL and the VP1 major capsid genes with Qiagen One StepRT PCR Kit. PCR products were sequenced with Big Dye Terminator v1.1in the Sequencer Analyser ABI Prism 3130 xl (PE Applied Biosystems).NoVs sequences were analysed using the Food borne Viruses in Europe(FBVE) network NoV genotyping tool and NCBI Blast. Results: Overall,14 (39%) samples were positive for the Sydney GII.4. variant. Theremaining 22 (61%) were also identified as GII.4 with a predominance <strong>of</strong>the New Orleans 2009 variant (16/22, 72.7%). Sydney variant was onlydetected from samples dating from June 2012.Conclusion: This is the first report <strong>of</strong> the circulation <strong>of</strong> NoV GII.4 Sydneyvariant in Portugal.REF 581Molecular dating in the evolution <strong>of</strong> primate bocavirusesIgor BABKIN 1 , Irina BABKINA 1 , Aleksandr TUMENTSEV 2 , ArtemTIKUNOV 1,2 , Aleksander KURILSHIKOV 1 , Nina TIKUNOVA 11 Institute <strong>of</strong> Chemical Biology and Fundamental Medicine, Novosibirsk,RUSSIA; 2 Novosibirsk State University, Novosibirsk, RUSSIAHuman bocavirus (HBoV) is associated with acute gastroenteritis inhumans, occurring mostly in young children and elderly people. Fourbocavirus genotypes have been found so far. Since there were no data onthe contribution <strong>of</strong> HBoV to gastroenteritis in Russia, 1781 fecal samplescollected from infants hospitalized with acute gastroenteritis in Novosibirsk,Russia during one year were tested for the presence <strong>of</strong> nucleicacids from HBoV and three major gastrointestinal viruses (rotavirus A,norovirus II, and astrovirus). HBoV was detected only in 1.9% <strong>of</strong> thesamples. Complete genome sequencing <strong>of</strong> three Novosibirsk isolates wasperformed. An evolutionary analysis <strong>of</strong> these sequences and the availableVi<strong>rologie</strong>, Vol 17, supplément 2, septembre 2013S281
5 th <strong>European</strong> <strong>Congress</strong> <strong>of</strong> <strong>Virology</strong>sequences <strong>of</strong> human and great apes bocaviruses demonstrated that thecurrent HBoV genotypes diverged comparatively recently, about 60–300years ago. The independent evolution <strong>of</strong> bocaviruses from chimpanzeesand gorillas commenced at the same time period. This suggests that theseisolates <strong>of</strong> great apes bocaviruses belong to separate genotypes within thespecies <strong>of</strong> human bocavirus, which is actually the primate bocavirus. Therate <strong>of</strong> mutation accumulation in the genome <strong>of</strong> primate bocaviruses hasbeen estimated. It has been demonstrated that HBoV1 diverged from theancestor common with chimpanzee bocavirus approximately 60–80 yearsago, while HBoV4 separated from great apes bocaviruses about 200–300years ago. The hypothesis postulating independent evolution <strong>of</strong> HBoV1and HBoV4 genotypes from primate bocaviruses has been proposed.REF 582Frequency <strong>of</strong> Rotavirus and Adenovirus in Children Between05yearsold in AnkaraGülendam BOZDAYI 8 , Kayhan CAGLAR 1 , Melda MERAL 1 , Ali AdilFOUAD 1 , Aylin ALTAY 1 , Yildiz DALLAR BILGE 2 , AyseKALKANCI 1 , Kamruddin AHMED 31 Gazi University, Faculty <strong>of</strong> Medicine, Department <strong>of</strong> Medical Microbiology,Ankara, TURKEY; 2 Ministry <strong>of</strong> Health, Ankara Training andEducation Hospital, Department <strong>of</strong> Pediatrics, Ankara,TURKEY; 3 OitaUniversity, Research Promotion Project, Yufu, Oita, JAPANObjectives: Acute gastroenteritis that observed in children are composedby mostly rotaviruses, human caliciviruses, enteric adenoviruses andastroviruses. Adenoviruses were isolated from 1.4% 10% <strong>of</strong> gastroenteritiscases which are observed in developing countries. In this study, determination<strong>of</strong> rotavirus group A and adenovirus serotype A F incidence wasaimed in children patients that applied to hospital because <strong>of</strong> acute gastroenteritis.Material and Methods: Stool samples were collected from286 patients attended to hospital with diarrhea and vomiting complaints.Rotavirus antigen in stool was detected by ELISA (Rotaclone, MeridianDiagnostics, Inc., Cincinnati, Ohio, USA). Adenovirus DNAs were acquiredfrom stool samples using ZR Fecal DNA KitTM (Zymo Research Corp.Irvine, USA). Acquired DNAs amplificated in LightCycler ® 2.0 (Roche,Germany) using WAYGENE ® Adenovirus nucleic acid detection kit (Berlin,Germany). Results: Rotavirus ELISA positivity was found in 77 (27%)<strong>of</strong> 286 patients involved in the study. Adenovirus PCR was found positivein 20 (7%) <strong>of</strong> the same patients’. While both rotavirus and adenovirus positivitywas detected 6 (2.2%) <strong>of</strong> patients, 6 (30%) <strong>of</strong> adenovirus positive 20patients, were rotavirus positive. Ten (50%) <strong>of</strong> adenovirus positive patientswere type F, 5 (25%) <strong>of</strong> were type B, 2 (13%) <strong>of</strong> were type E and 1 (7%)<strong>of</strong> was found type A, however 2 (13%) <strong>of</strong> them could not be determined.Conclusion: Our results were evaluated as similar results with previousstudies in our country. In proportion to similar studies,we indicated a lowerresult as 2.2% about association <strong>of</strong> two viruses in our study. This situationmakes us think that both two viruses could be observed at the same time,at the same host and could have been taken by the same way.REF 583Rotavirus genotypes G9 and G2 are co dominantly circlating inAnkara, Turkey: a shift <strong>of</strong> genotype distribution by emerging G9strainsGulendam BOZDAYI 1 , Aylin ALTAY 1 ,Ayça YENIARAS 2 , YildizDALLAR BILGE 2 , Kamruddin AHMED 31 Gazi University, Faculty <strong>of</strong> Medicine, Department <strong>of</strong> Medical Microbiology,Ankara, TURKEY; 2 Ministry <strong>of</strong> Health, Ankara Training andEducation Hospital, Department <strong>of</strong> Pediatrics, Ankara, TURKEY; 3 OitaUniversity, Research Promotion Project, Yufu, Oita, JAPANObjectives: Globally, rotavirus is the leading cause <strong>of</strong> diarrhea in childrenunder 5 years <strong>of</strong> age. The purpose <strong>of</strong> this study was to detect the frequency<strong>of</strong> rotavirus infection and genotype distribution in children under 5 yearsold attending with acute diarrhea to a hospital in Ankara, Turkey. Materialsand Methods: Stool specimens were collected from 269 childrenattended to Ankara Training and Education Hospital with acute diarrheafrom January 2010 to July 2011. Rotavirus antigen in stool was detectedby commercially available ELISA kit androtavirus genomic dsRNA wasextracted from the ELISA positive samples using phenol chlor<strong>of</strong>orm isoamylalcohol method. Amplification <strong>of</strong> genotype specific geneswas carriedout by nested RT PCR. Results: Among 269 samples, 29.7% were positivefor rotavirus. Rotavirus mainly affected (45.7%) children <strong>of</strong> 12-23 monthsage group. In spring and winter roatavirus infection was more frequent,36.7% and 36.4%, respectively. G and P types were detected in 88.7% and91.2% <strong>of</strong> rotavirus positive samples, respectively. The frequency <strong>of</strong> differentG type detection was as follow: G2 (35.2%) and G9 (45.1%) werethe most prevalent types.G1, G3, G4, G1+G9 and G2+G9 were detectedin 8.4%,5.6%, 2.8%, 1.4% and 1.4% <strong>of</strong> samples, respectively.WithinP genotypes, P8 was detected in 93.1%, P4 in5.5% and P4+P8 in 1.4%<strong>of</strong> samples. The dominant G and P genotype combinations were, G2P[8](33.8%) and G9P[8] (39.4%). Conclusion: The frequency <strong>of</strong> P genotypedistribution in this study was similar to that <strong>of</strong> detected in previous years.Compared with previous study there was a significant increase <strong>of</strong> genotypeG9 and G2 in 2010-2011. Almost half <strong>of</strong> G genotypes were G9 indicatingthat this genotype is emerging in Ankara, Turkey. It is necessary to continuesurveillance in the coming yearsto understand the epidemiology andevolution <strong>of</strong> genotype G9 in Ankara and other parts <strong>of</strong> Turkey.REF 584Norovirus infections and prevalence <strong>of</strong> IgG antibodies to genotypeGII.4 in a Spanish populationJavier BUESA 1,2 , Noelia CARMONA VICENTE 1 , ManuelFERNANDEZ JIMENEZ 1 , Juan M. RIBES FERNANDEZ 1 , Carlos J.TELLEZ CASTILLO 11 School <strong>of</strong> Medicine, University <strong>of</strong> Valencia, Microbiology, Valencia,SPAIN; 2 Hospital Clinico Universitario, Valencia, SPAINNoroviruses (NoVs) are responsible for most <strong>of</strong> the outbreaks <strong>of</strong> acutegastroenteritis worldwide, as well as a common cause <strong>of</strong> sporadic cases.The prevalence <strong>of</strong> different NoVs genotypes as the cause <strong>of</strong> acute gastroenteritisin the region <strong>of</strong> Valencia (Spain) during a three year period(2008 10) was investigated. In addition, the prevalence <strong>of</strong> IgG antibodiesto NoV genotype GII.4 in sera from a random sample <strong>of</strong> individualsduring the same period <strong>of</strong> time was determined. Baculovirus expressedvirus like particles (VLPs) <strong>of</strong> NoV GII.4 2006b and a recombinant P2polypeptide <strong>of</strong> NoV GII.4 2008 produced in Escherichia coli were usedas coating antigens in enzyme immunoassays to study NoV GII.4 specificantibodies. Serum samples from 434 individuals <strong>of</strong> different ages collectedbetween 2009 and 2010 were assayed. NoVs were detected in 42 (77.3%)outbreaks and in 7.8% sporadic cases <strong>of</strong> acute gastroenteritis. GenogroupGII strains were predominant causing both outbreaks and sporadic cases.Different genotype GII.4 viral variants were found throughout the studyperiod (GII.4 2006a, 2006b, 2008 and 2010), being the GII.4 2010 variantthe most frequently detected (40%). Antibodies to the P2 polypeptide andto GII.4 VLP were detected in practically all (99%) <strong>of</strong> the serum samplesanalysed. Titers <strong>of</strong> antibodies to NoV VLPs and to the P2 domain graduallyincrease with age, reaching their highest concentrations in the forthdecade <strong>of</strong> life. Our results suggest that exposure to NoV genotype GII.4occurs early in childhood but re infections are common.REF 585Detection and first molecular characterization <strong>of</strong> Canine parvovirus(CPV) on dogs in TurkeyTaner KARAOGLU, Sepandar GARGARI, Aykut ÖZKULAnkara University, Faculty <strong>of</strong> Veterinary Medicine, Department <strong>of</strong> <strong>Virology</strong>,Ankara, TURKEYS282 Vi<strong>rologie</strong>, Vol 17, supplément 2, septembre 2013
- Page 3 and 4:
Contents5 th European Congress of V
- Page 5 and 6:
i r o l o g i eList of Keynote Spea
- Page 7 and 8:
i r o l o g i eList of Chairpersons
- Page 9 and 10:
i r o l o g i eWelcomeWelcome to th
- Page 11 and 12:
5 th European Congress of VirologyY
- Page 13 and 14:
i r o l o g i eExhibitorsThe indust
- Page 15:
i r o l o g i eFacilities for the 5
- Page 18 and 19:
i r o l o g i eGeneral Information
- Page 20 and 21:
PROGRAMME AT A GLANCEWednesday 11th
- Page 22 and 23:
5 th European Congress of VirologyW
- Page 24 and 25:
5 th European Congress of VirologyW
- Page 26 and 27:
5 th European Congress of VirologyW
- Page 28 and 29:
5 th European Congress of VirologyW
- Page 30 and 31:
5 th European Congress of VirologyW
- Page 32 and 33:
Scientific Programme -Saturday 14 t
- Page 34 and 35:
5 th European Congress of Virology1
- Page 36 and 37:
5 th European Congress of VirologyW
- Page 38 and 39:
5 th European Congress of VirologyW
- Page 40 and 41:
5 th European Congress of VirologyW
- Page 42 and 43:
5 th European Congress of VirologyW
- Page 44 and 45:
5 th European Congress of VirologyW
- Page 46 and 47:
5 th European Congress of VirologyW
- Page 48 and 49:
5 th European Congress of VirologyT
- Page 50 and 51:
5 th European Congress of VirologyT
- Page 52 and 53:
5 th European Congress of VirologyT
- Page 54 and 55:
5 th European Congress of VirologyR
- Page 56 and 57:
5 th European Congress of VirologyR
- Page 58 and 59:
5 th European Congress of Virologyw
- Page 60 and 61:
5 th European Congress of VirologyT
- Page 62 and 63:
5 th European Congress of VirologyR
- Page 64 and 65:
5 th European Congress of Virologyt
- Page 66 and 67:
5 th European Congress of VirologyR
- Page 68 and 69:
5 th European Congress of VirologyT
- Page 70 and 71:
5 th European Congress of VirologyA
- Page 72 and 73:
5 th European Congress of Virologyp
- Page 74 and 75:
5 th European Congress of VirologyR
- Page 76 and 77:
5 th European Congress of VirologyF
- Page 78 and 79:
5 th European Congress of VirologyF
- Page 80 and 81:
5 th European Congress of Virologyc
- Page 82 and 83:
5 th European Congress of VirologyF
- Page 84 and 85:
5 th European Congress of VirologyF
- Page 86 and 87:
5 th European Congress of Virologyt
- Page 88 and 89:
5 th European Congress of VirologyH
- Page 90 and 91:
5 th European Congress of VirologyF
- Page 92 and 93:
5 th European Congress of VirologyR
- Page 94 and 95:
5 th European Congress of VirologyR
- Page 96 and 97:
5 th European Congress of VirologyS
- Page 98 and 99:
5 th European Congress of VirologyS
- Page 100 and 101:
5 th European Congress of VirologyS
- Page 102 and 103:
5 th European Congress of VirologyS
- Page 104 and 105:
5 th European Congress of VirologyA
- Page 106 and 107:
5 th European Congress of Virology1
- Page 108 and 109:
5 th European Congress of Virology1
- Page 110 and 111:
5 th European Congress of VirologyS
- Page 112 and 113:
5 th European Congress of VirologyS
- Page 114 and 115:
5 th European Congress of VirologyS
- Page 116 and 117:
5 th European Congress of VirologyS
- Page 118 and 119:
Virologie 2013, 17 (supplément 2)
- Page 120 and 121:
5 th European Congress of VirologyA
- Page 122 and 123:
5 th European Congress of Virology0
- Page 124 and 125:
5 th European Congress of Virology0
- Page 126 and 127:
5 th European Congress of VirologyH
- Page 128 and 129:
5 th European Congress of Virologys
- Page 130 and 131:
5 th European Congress of Virology0
- Page 132 and 133:
5 th European Congress of Virologyf
- Page 134 and 135:
5 th European Congress of VirologyE
- Page 136 and 137:
5 th European Congress of Virologyt
- Page 138 and 139:
5 th European Congress of VirologyA
- Page 140 and 141:
5 th European Congress of Virologyp
- Page 142 and 143:
5 th European Congress of Virology0
- Page 144 and 145:
5 th European Congress of Virologyi
- Page 146 and 147:
5 th European Congress of Virologyr
- Page 148 and 149:
5 th European Congress of Virologyi
- Page 150 and 151:
5 th European Congress of Virologyp
- Page 152 and 153:
5 th European Congress of Virology3
- Page 154 and 155:
5 th European Congress of VirologyR
- Page 156 and 157:
5 th European Congress of Virology0
- Page 158 and 159:
5 th European Congress of Virologyt
- Page 160 and 161:
5 th European Congress of VirologyB
- Page 162 and 163:
5 th European Congress of Virologyr
- Page 164 and 165:
5 th European Congress of VirologyR
- Page 166 and 167:
5 th European Congress of Virologyi
- Page 168 and 169:
5 th European Congress of VirologyI
- Page 170 and 171:
5 th European Congress of Virologyf
- Page 172 and 173:
5 th European Congress of Virologya
- Page 174 and 175:
5 th European Congress of VirologyS
- Page 176 and 177:
5 th European Congress of Virology1
- Page 178 and 179:
5 th European Congress of Virologyt
- Page 180 and 181:
5 th European Congress of VirologyV
- Page 182 and 183:
5 th European Congress of Virologyc
- Page 184 and 185:
5 th European Congress of Virologyw
- Page 186 and 187:
5 th European Congress of Virologyt
- Page 188 and 189:
5 th European Congress of Virologya
- Page 190 and 191:
5 th European Congress of VirologyA
- Page 192 and 193:
5 th European Congress of Virologyn
- Page 194 and 195:
5 th European Congress of Virologyi
- Page 196 and 197:
5 th European Congress of Virologyw
- Page 198 and 199:
5 th European Congress of VirologyT
- Page 200 and 201:
5 th European Congress of Virology(
- Page 202 and 203:
5 th European Congress of Virologya
- Page 204 and 205:
5 th European Congress of Virology1
- Page 206 and 207:
5 th European Congress of Virologyo
- Page 208 and 209:
5 th European Congress of VirologyI
- Page 210 and 211:
5 th European Congress of VirologyR
- Page 212 and 213:
5 th European Congress of Virologyw
- Page 214 and 215:
5 th European Congress of Virologyt
- Page 216 and 217:
5 th European Congress of Virologya
- Page 218 and 219:
5 th European Congress of Virologyp
- Page 220 and 221:
5 th European Congress of Virologya
- Page 222 and 223:
5 th European Congress of Virology(
- Page 224 and 225:
5 th European Congress of Virologyt
- Page 226 and 227:
5 th European Congress of Virologyn
- Page 228 and 229:
5 th European Congress of Virologyi
- Page 230 and 231:
5 th European Congress of Virologyo
- Page 232 and 233: 5 th European Congress of Virology2
- Page 234 and 235: 5 th European Congress of VirologyR
- Page 236 and 237: 5 th European Congress of Virology7
- Page 238 and 239: 5 th European Congress of VirologyR
- Page 240 and 241: 5 th European Congress of VirologyR
- Page 242 and 243: 5 th European Congress of Virologya
- Page 244 and 245: 5 th European Congress of Virologyc
- Page 246 and 247: 5 th European Congress of Virologya
- Page 248 and 249: 5 th European Congress of Virologyh
- Page 250 and 251: 5 th European Congress of Virology6
- Page 252 and 253: 5 th European Congress of VirologyC
- Page 254 and 255: 5 th European Congress of VirologyM
- Page 256 and 257: 5 th European Congress of Virologyi
- Page 258 and 259: 5 th European Congress of Virology2
- Page 260 and 261: 5 th European Congress of Virologyf
- Page 262 and 263: 5 th European Congress of VirologyR
- Page 264 and 265: 5 th European Congress of Virologyw
- Page 266 and 267: 5 th European Congress of VirologyM
- Page 268 and 269: 5 th European Congress of VirologyI
- Page 270 and 271: 5 th European Congress of Virologyp
- Page 272 and 273: 5 th European Congress of Virologyu
- Page 274 and 275: 5 th European Congress of VirologyO
- Page 276 and 277: 5 th European Congress of Virologys
- Page 278 and 279: 5 th European Congress of Virology2
- Page 280 and 281: 5 th European Congress of Virologyf
- Page 284 and 285: 5 th European Congress of VirologyA
- Page 286 and 287: 5 th European Congress of VirologyI
- Page 288 and 289: 5 th European Congress of VirologyB
- Page 290 and 291: 5 th European Congress of VirologyD
- Page 292 and 293: 5 th European Congress of VirologyG
- Page 294 and 295: 5 th European Congress of VirologyJ
- Page 296 and 297: 5 th European Congress of VirologyL
- Page 298 and 299: 5 th European Congress of VirologyN
- Page 300 and 301: 5 th European Congress of VirologyR
- Page 302 and 303: 5 th European Congress of VirologyS
- Page 304 and 305: 5 th European Congress of VirologyW